Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II therapeutic HIV vaccine study of ChAdOx1.tHIVconsvX prime and MVA.tHIVconsvX boost versus placebo
2024-514581-39-00Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Nov 2023
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ChAdOx1 tHIVconsvX and MVA tHIVconsvX in human immunodeficiency virus infection (HIV) (2 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoints: Safety and Immunogenicity. Started Nov 2023; status: completed.
02
Drugs
ChAdOx1 tHIVconsvXMVA tHIVconsvX
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-514581-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514581-39-00.